Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
BOSTON, Jan. 28, 2016 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Medical Officer, Evan Loh, M.D., will participate in the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10 with a fireside chat from 9:15 to 9:35 a.m. The conference is being held at the Waldorf Astoria in New York City. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.
To access the live webcast of Paratek's session, please visit http://wsw.com/webcast/leerink26/prtk. Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed in the investor section of http://www.paratekpharma.com for a minimum of 90 days following the live presentation.
About Paratek
Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Paratek initiated a Phase 3 registration study in ABSSSI in June 2015 to determine the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for CABP with omadacycline was initiated in November 2015.
Omadacycline is a new once-daily oral and IV, well-tolerated broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, complicated urinary tract infections (cUTI), and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a new once-daily oral tetracycline-derived compound for the potential treatment of acne and rosacea in the community setting. Sarecycline is designed to be a well-tolerated, once-daily, oral, narrow spectrum antibiotic with anti-inflammatory properties. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Two identical Phase 3 registration studies were initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.
For more information, visit www.paratekpharma.com.
CONTACTS: Media Relations: Michael Lampe (484) 575-5040 [email protected] Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568
